GlassScriptPhysician profile
Francisca Porras
NPI 1215585161
$3,623.44
in general payments reported to CMS, 2019-2025
31 companies · $71.19 in 2025
The $71.19 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,355 · 2023: $1,020 · 2024: $1,178 · 2025: $71.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,799 · Education: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,798.96 |
| Education | $469.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $549.74 | 2022-2023 | Padcev |
| Janssen Biotech, INC. | $432.75 | 2022-2024 | Erleada, Tecvayli, Carvykti |
| Pfizer INC. | $370.01 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $194.62 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $194.40 | 2023-2024 | Calquence, Lynparza, Enhertu |
| Fresenius Kabi USA, LLC | $187.67 | 2024 | Stimufend |
| Takeda Pharmaceuticals U.S.A., INC. | $178.84 | 2022-2024 | Fruzaqla |
| Lilly USA, LLC | $141.76 | 2022-2024 | Jaypirca, Verzenio |
| Genzyme Corporation | $140.88 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $130.99 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $125.00 | 2023 | Monoferric |
| Rigel Pharmaceuticals, INC. | $121.82 | 2022 | |
| Janssen Scientific Affairs, LLC | $119.07 | 2022 | |
| Kite Pharma, INC. | $110.27 | 2022-2023 | |
| Astellas Pharma US INC | $99.00 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $97.69 | 2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $73.36 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $71.19 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $41.63 | 2023-2024 | Libtayo |
| Immunocore Limited | $27.60 | 2023 | Kimmtrak |
| Genentech USA, INC. | $25.07 | 2024 | Tecentriq, Polivy |
| Morphosys, US INC. | $24.75 | 2023 | Monjuvi |
| Tersera Therapeutics LLC | $22.97 | 2024 | Zoladex |
| Apellis Pharmaceuticals, INC. | $20.75 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.56 | 2024 | |
| Daiichi Sankyo INC. | $20.48 | 2024 | Enhertu |
| Sobi, INC | $19.54 | 2023 | |
| Karyopharm Therapeutics INC. | $15.91 | 2023 | Xpovio |
| Kyowa Kirin, INC. | $15.60 | 2024 | Poteligeo |
| Array Biopharma INC | $15.43 | 2024 | Lorbrena, Braftovi, Xalkori |
| Agios Pharmaceuticals, INC. | $14.09 | 2023 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francisca Porras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.